{"response": {"meta": {"time": 25, "hits": 3, "offset": 0}, "docs": [{"news_desk": null, "document_type": "blogpost", "_id": "4fd363f18eb7c8105d8b29ee", "headline": {"kicker": "The Learning Network", "main": "Making the Global Local"}, "pub_date": "2005-12-14T01:33:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By ANNISSA HAMBOUZ and JAVAID KHAN", "person": [{"lastname": "HAMBOUZ", "rank": 1, "firstname": "Annissa", "organization": "", "role": "reported"}, {"lastname": "KHAN", "rank": 2, "firstname": "Javaid", "organization": "", "role": "reported"}]}, "abstract": "In this lesson, students learn about the marketing and production of the children's television program \"Sesame Street\" in various countries around the world. They then create a character for a children's program that reflects the current issues and values of their communities.", "web_url": "http://learning.blogs.nytimes.com/2005/12/14/making-the-global-local/", "section_name": "U.S.", "lead_paragraph": "Note: This lesson was originally published on an older version of The Learning Network; the link to the related Times article will take you to a page on the old site.", "snippet": "In this lesson, students learn about the marketing and production of the children's television program \"Sesame Street\" in various countries around the world. They then create a character for a children's program that reflects the current issues and...", "blog": [], "keywords": [{"rank": "1", "value": "News", "name": "type_of_material"}], "print_page": null, "type_of_material": "Blog", "word_count": 2311, "subsection_name": null, "multimedia": []}, {"news_desk": "Business/Financial Desk", "document_type": "article", "_id": "4fd24e268eb7c8105d7efa45", "headline": {"kicker": "FIVE DAYS", "main": "Boston Scientific's Guidant Bid Muddies the Water"}, "pub_date": "2005-12-10T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By Mark A. Stein", "person": [{"middlename": "A.", "organization": "", "role": "reported", "rank": 1, "firstname": "Mark", "lastname": "Stein"}]}, "abstract": null, "web_url": "http://www.nytimes.com/2005/12/10/business/10five.ready.html", "section_name": "Business", "lead_paragraph": "HOLIDAY preparations did not slow the deal makers, who were busy from the heart of Wall Street to Beijing. The economy showed some encouraging signs of health, even while some doctors were concluding that junk food ads were to blame for the lack of health in young people. CONTRE-RIPOSTE -- A messy megamerger got a little messier when Boston Scientific stepped in front of its bitter rival, Johnson & Johnson, to make an unsolicited offer to acquire Guidant, a maker of implantable heart devices. Boston Scientific offered $25 billion, which was about what Johnson & Johnson originally bid -- before reducing its offer after Guidant recalled some defective products.", "snippet": "HOLIDAY preparations did not slow the deal makers, who were busy from the heart of Wall Street to Beijing. The economy showed some encouraging signs of health, even while some doctors were concluding that junk food ads were to blame for the lack of...", "blog": [], "keywords": [], "print_page": "2", "type_of_material": "News", "word_count": 907, "subsection_name": null, "multimedia": []}, {"news_desk": "Business/Financial Desk", "document_type": "article", "_id": "4fd262fa8eb7c8105d814eba", "headline": {"main": "Nerve Stimulation and Revenue Growth"}, "pub_date": "2005-12-09T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By BARNABY J. FEDER", "person": [{"middlename": "J.", "organization": "", "role": "reported", "rank": 1, "firstname": "Barnaby", "lastname": "FEDER"}]}, "abstract": "Boston Scientific's bid to acquire Guidant, maker of stents and other devices used to treat circulatory illnesses, raises questions about its 15 percent stake in Cyberonics, whose implanted nerve-stimulation device, VNS Therapy System, was approved in July for treatment of severe depression; Medicare and many major insurers continue to classify treatment as experimental, and there are conflicting views on Wall Street of technology's prospects; there are reports that Boston Scientific might sell its stake in Cyberonics to raise cash if its bid for Guidant is successful; among potential buyers would be Johnson & Johnson, Boston Scientific's rival for Guidant; photo (M)", "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9C0DEFD61031F93AA35751C1A9639C8B63", "section_name": "Business", "lead_paragraph": "An unexpected takeover battle between Boston Scientific and Johnson & Johnson for control of Guidant seems bound to send aftershocks through the medical device industry. There is widespread speculation about the effects on prominent competitors like Medtronic and St. Jude Medical in Guidant's main business of electrical implants that regulate heart functioning. Investors and analysts also wonder who will end up with Guidant's business of making stents and other devices used to treat circulatory illnesses.", "snippet": "An unexpected takeover battle between Boston Scientific and Johnson & Johnson for control of Guidant seems bound to send aftershocks through the medical device industry.      There is widespread speculation about the effects on prominent competitors...", "blog": [], "keywords": [{"value": "CYBERONICS INC", "name": "organizations"}, {"value": "JOHNSON & JOHNSON INC", "name": "organizations"}, {"value": "BOSTON SCIENTIFIC CORP", "name": "organizations"}, {"value": "GUIDANT CORP", "name": "organizations"}, {"value": "HEART", "name": "subject"}, {"value": "MERGERS, ACQUISITIONS AND DIVESTITURES", "name": "subject"}, {"value": "MENTAL HEALTH AND DISORDERS", "name": "subject"}, {"value": "DEPRESSION (MENTAL)", "name": "subject"}], "print_page": "3", "type_of_material": "News", "word_count": 1076, "subsection_name": null, "multimedia": []}]}, "status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}